Alamar Biosciences (ALMR) upsized its IPO at pricing – to 11.25 million shares – up from 9.38 million in the prospectus – and priced its IPO at $17.00 – the high end of its range – to raise $191.25 million on Thursday night, April 16, 2026. Alamar Biosciences is expected to start trading tomorrow – Friday, April 17 – on the NASDAQ. The Alamar IPO had been marketed at a price range of $15.00 to $17.00.
At pricing, Alamar Biosciences had a market cap of about $1.14 billion.
J.P.Morgan and BofA Securities led the joint book-running team, which included TD Cowen, Leerink Partners and Stifel.
Alamar Biosciences, based in Fremont, California, is a commercial-stage proteomics company with an initial focus on early detection of Alzheimer’s disease. Alamar’s blood test to measure brain-derived-pTau217 uses “a small blood sample, offering a noninvasive, economical and convenient alternative to cerebrospinal fluid sample tests or PET scans,” the prospectus said.
Alamar Biosciences is not profitable, according to the prospectus: The company reported a net loss of $29.78 million on revenue of $74.2 million for the 12 months that ended Dec. 31, 2025.
(For more information about this company, please check the IPO Calendar and the individual IPO Profile found on the IPOScoop.com website.)
Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.
To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.
Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.